Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Income from Continuing Operations (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Income from Continuing Operations for 11 consecutive years, with 92234000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations rose 26.69% to 92234000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 411795000.0, a 15.35% increase, with the full-year FY2025 number at 411795000.0, up 15.35% from a year prior.
  • Income from Continuing Operations was 92234000.0 for Q4 2025 at Intellia Therapeutics, up from 104763000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 46205000.0 in Q1 2021 to a low of 143706000.0 in Q1 2022.
  • A 5-year average of 103994950.0 and a median of 104159000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 211.02% in 2022, then surged 30.43% in 2023.
  • Intellia Therapeutics' Income from Continuing Operations stood at 79912000.0 in 2021, then tumbled by 31.06% to 104733000.0 in 2022, then dropped by 21.67% to 127433000.0 in 2023, then grew by 1.27% to 125816000.0 in 2024, then increased by 26.69% to 92234000.0 in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Income from Continuing Operations are 92234000.0 (Q4 2025), 104763000.0 (Q3 2025), and 102594000.0 (Q2 2025).